Want to see INGN full AI Analyst Report?
INGN Stock Chart & Stats
$6.21
$0.43(4.59%)
At close: 4:00 PM EST
$6.21
$0.43(4.59%)
Day’s Range― - ―
52-Week Range$5.34 - $9.13
Previous CloseN/A
Volume110.44K
Average Volume (3M)387.79K
Market Cap
$177.07M
Enterprise Value$94.99M
Total Cash (Recent Filing)$111.47M
Total Debt (Recent Filing)$16.93M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding27,074,516
10 Day Avg. Volume310,281
30 Day Avg. Volume387,791
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.95
Price to Sales (P/S)0.52
P/FCF Ratio-8.46
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue0.27
Enterprise Value/Gross Profit0.55
Enterprise Value/Ebitda-18.16
Forecast
1Y Price Target
$12.00Price Target Upside93.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$369.27M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA strong liquidity position and zero debt provide durable financial flexibility to fund product launches, clinical programs and international expansion without immediate refinancing risk. This supports execution through the current unprofitable transition and cushions cash burn while management scales operations.
Product DifferentiationLonger device useful life and superior serviceability create a structural competitive edge: larger installed base, stronger replacement/accessory demand and higher lifetime value per patient. Combined with growing outcomes data, this supports premium positioning and more durable margins over time.
International ExpansionMeaningful international growth diversifies revenue away from a weak U.S. channel and taps higher-growth markets via tenders and HME relationships. Regional expansion can smooth seasonality and create sustainable multi-geography revenue streams supporting long-term top-line resilience.
Bears Say
Negative Cash FlowPersistently negative free cash flow and sharply worsening FCF growth reduce the firm's ability to self-fund working capital and growth. Even with cash on hand, ongoing cash burn pressures capital allocation, limits optionality for investments, and risks depleting reserves if profitability doesn't improve.
Profitability DeficitDespite margin improvement, sustained GAAP losses and negative adjusted EBITDA signal the business hasn't reached durable earnings power. Continued operating losses constrain reinvestment, reduce ability to build reserves, and prolong dependence on liquidity while the company scales new products.
U.S. Channel HeadwindsStructural conversion in the U.S. market is pressuring direct-to-consumer and rental channels, eroding a historically stable revenue stream. Weakness in U.S. sales and rentals reduces recurring revenue predictability and forces greater reliance on international rollouts and new products to restore long-term growth.
Inogen News
INGN FAQ
What was Inogen Inc’s price range in the past 12 months?
Inogen Inc lowest stock price was $5.34 and its highest was $9.13 in the past 12 months.
What is Inogen Inc’s market cap?
Inogen Inc’s market cap is $177.07M.
When is Inogen Inc’s upcoming earnings report date?
Inogen Inc’s upcoming earnings report date is Aug 12, 2026 which is in 30 days.
How were Inogen Inc’s earnings last quarter?
Inogen Inc released its earnings results on May 07, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.283 by -$0.017.
Is Inogen Inc overvalued?
According to Wall Street analysts Inogen Inc’s price is currently Undervalued.
Does Inogen Inc pay dividends?
Inogen Inc does not currently pay dividends.
What is Inogen Inc’s EPS estimate?
Inogen Inc’s EPS estimate is -0.15.
How many shares outstanding does Inogen Inc have?
Inogen Inc has 27,074,516 shares outstanding.
What happened to Inogen Inc’s price movement after its last earnings report?
Inogen Inc reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.283. Following the earnings report the stock price went down -2.364%.
Which hedge fund is a major shareholder of Inogen Inc?
Currently, no hedge funds are holding shares in INGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inogen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (93.24% Upside)
$12.00 (93.24% Upside)
Blogger Sentiment
Bullish
INGN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 469.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.54%
12-Months-Change
Fundamentals
Return on Equity
-12.90%
Trailing 12-Months
Asset Growth
-7.29%
Trailing 12-Months
Company Description
Inogen Inc
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
INGN Stock 12 Month Forecast
Average Price Target
$12.00
▲(93.24% Upside)
Technical Analysis
Ownership Overview
3.57% Insiders
16.63% Mutual Funds
0.45% Other Institutional Investors
69.39% Public Companies and
Individual Investors